statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company developing investigational first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies, today...

Geron Corporation Reports First Quarter 2024 Financial Results and Business Highlights

Latest Ratings for GERN
 DateFirmActionFromTo Nov 2021BairdInitiates Coverage OnOutperform Aug 2020HC Wainwright & Co.MaintainsBuy Aug 2020StifelInitiates Coverage OnBuy
 View More Analyst...

Navigating 10 Analyst Ratings For Geron

Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that it will release its first quarter 2024 financial results and business highlights before the...

Geron to Announce First Quarter 2024 Financial Results on May 2, 2024

Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today reported that it has granted non-statutory stock options to purchase an aggregate of 243,000 shares of Geron...

Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

The Latest Analyst Ratings For Geron

China Universal Asset Management Co. Ltd. lifted its position in shares of Geron Co. (NASDAQ:GERN - Free Report) by 367.9% in the 4th quarter, according to the company in its most recent Form 13F...

China Universal Asset Management Co. Ltd. Acquires 49,394 Shares of Geron Co. (NASDAQ:GERN)

Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that John A. Scarlett, M.D., Gerons Chairman and Chief Executive Officer, is scheduled to present at...

Geron to Participate at Upcoming Investor Conferences in April

Geron Co. (NASDAQ:GERN - Get Free Report) was the target of a significant growth in short interest during the month of March. As of March 15th, there was short interest totalling 50,950,000 shares, a...

Geron Co. (NASDAQ:GERN) Sees Large Growth in Short Interest

Investors in Geron Corp. (GERN) saw new options become available today, for the August 16th expiration...

Interesting GERN Put And Call Options For August 16th

Investors in Geron Corp. (GERN) saw new options become available today, for the May 3rd expiration...

GERN May 3rd Options Begin Trading

Geron Corp. operates as a biotechnology company. It develops a telomerase inhibitor, Imetelstat, in hematologic myeloid malignancies. The firm develops therapeutic products for oncology. The company was founded by Michael D. West on November 28, 1990 and is headquartered in Foster City, CA.

Watchers	20,963
52-Wk Low	$1.64
52-Wk High	$4.30

Volume	811.00
52-Wk High	$4.30
52-Wk Low	$1.64

Period	Estimated	Reported	Surprise	Result
Q2'24	-$0.10	--	--	N/A
Q1'24	-$0.10	-$0.09	5.97%	BEAT
Q4'23	-$0.11	-$0.09	14.29%	BEAT
Q3'23	-$0.10	-$0.08	17.24%	BEAT
Q2'23	-$0.08	-$0.09	-8.00%	MISSED

GERN Geron Corp.

About

Feed

News

Sentiment

Earnings

Fundamentals